Enanta Pharmaceuticals (NASDAQ:ENTA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $27.00 price target on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Evercore ISI raised shares of Enanta Pharmaceuticals to a strong-buy rating in a report on Tuesday, August 6th. JMP Securities reaffirmed a market outperform rating and issued a $22.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. cut their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating on the stock in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $20.00.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $11.04 on Thursday. The stock has a market capitalization of $233.82 million, a PE ratio of -1.77 and a beta of 0.58. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $17.80. The business has a 50 day simple moving average of $11.92 and a two-hundred day simple moving average of $13.18.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company had revenue of $17.97 million for the quarter, compared to analysts’ expectations of $17.44 million. During the same quarter in the previous year, the business posted ($1.27) earnings per share. Enanta Pharmaceuticals’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts anticipate that Enanta Pharmaceuticals will post -5.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals during the 1st quarter valued at $118,000. Vanguard Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 7.5% during the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 1.3% in the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after purchasing an additional 10,952 shares during the last quarter. Virtu Financial LLC purchased a new position in Enanta Pharmaceuticals in the 1st quarter worth about $191,000. Finally, Farallon Capital Management LLC increased its stake in Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after buying an additional 70,000 shares during the period. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.